LIFEAI

The current treatments for depression are not working, and there is a need for a significant step change in the way we treat mental health conditions. Excited to discuss new treatments for depression and the progress of our portfolio company MindBio Therapeutic's (CSE: MBIO) in Phase 2B Microdosing Depression clinical trials. We are entering our 25th participant into this randomized, double dummy, triple-blind, active placebo-controlled clinical trial. Join me for this important conversation. #depression #mentalhealth #clinicaltrials

We must continue to advance this important scientific work to find better treatments for depression and related conditions. 🔥 Data from MindBio’s Phase 2A Depression trial indicates improvements in a range of secondary outcome measures following an 8-week treatment course with MB22001. This includes a 52% reduction in anxiety (HAM-A), and self-reported reductions in stress (35%), anxiety (59%) and depression (40%) using the DASS questionnaire. Participant’s psychological quality of life was improved by 37% as measured by the WHOQOL. 👨🎓 Earlier this year MindBio reported primary data from this trial which demonstrated a 14.1 point drop in MADRS Score (Montgomery-Asberg Depression Rating Scale), which is a 60% overall drop in depressive symptoms and a 53% complete remission from depression. 😃 Importantly, the Company looks forward to reporting the durability of antidepressant response from treatment with MB22001 at 1 months and 3 months post treatment follow up shortly.

MindBio Therapeutics explores psychedelic potential of LSD for depression, PMS writes Tamra Sami for Clarivate's BioWorld The use of psychedelics is seeing impressive results in treating psychiatric disorders like treatment-resistant depression and post-traumatic stress disorder, and Mindbio Therapeutics is expanding the field to include microdoses of lysergic acid diethylamide (LSD) to treat depression and premenstrual syndrome. 📰 Read full article: https://lnkd.in/dV5PsAs9

The impact of under-representation of women in clinical trials is significant and has resulted in an over-representation of serious adverse events and side effects from prescribed medications in women. Tune into Dr Rachael Sumner, who discusses the issues and the team's approach in newly approved clinical trials for negative mood symptom alleviation in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

It's a marathon in clinical research, and despite market conditions the progress in the company's clinical work has been exceptionally strong. MindBio Therapeutics has a multiple Phase 2B clinical trial program underway and is making terrific progress with novel treatments for depressive disorders. 🔥 Now Canadian Securities Exchange listed MindBio Therapeutics (CNSX:MBIO) is exploring a senior exchange listing as it readies for Phase 3 trials. 🙏 Grateful for the support of investors, colleagues, friends and supporters as this Hardenbrook Group portfolio company enters its next stage of growth.

👩🏫 Women are under-represented in clinical research particularly early stage medical research, due to a number of reasons, pregnancy, menstrual cycle and other excuses. The approach in clinical science has surprised me, even in our own work, that men are more commonly used in early research and women are introduced in later trials. It's no surprise then that women are over represented compared to men in serious adverse events and side effects from prescribed medications. 🔥 So, in what appears to a first of its kind, certainly with this type of medicine, our team have designed and had approved a series of CNS medicine trials focused on women's health assessing the pharmacokinetic and pharmacodynamic effects of a CNS medicine over key phases of the menstrual cycle. 📣 The trials will study the effects of microdosing MB22001 in healthy menstruating persons and people suffering from Pre-Menstrual Syndrome and Pre-Menstrual Dysphoric Disorder. The symptoms of PMS and PMDD only exist as a result of and are exacerbated by certain stages by the menstrual cycle. 😀 The thesis is that during the luteal phase of the menstrual cycle (where the negative mood symptoms of PMS and PMDD symptoms escalate) microdosing of MB22001 will help alleviate the symptoms of PMS and PMDD without the side effects of commonly used antidepressants and the oral contraceptive pill. It's a significant development for progressing CNS medicine research in women's health.

It's all about sleep! 👨🔬 The research into the use of this novel treatment for depression and its positive effect on mood, improving depressive symptoms and now sleep is fascinating and supportive of continuing MB22001 into late stage clinical trials. 🏁 There is certainly no stop sign that I can see from a very broad set of data we have collected and minimal side effects and no serious adverse events, so we progress. 👨🎓 MindBio is at the forefront of developing microdosing treatments that are currently being tested safely out in the community in clinical trials. We believe the treatment is a scalable way to use these medicines that ordinarily, in large doses are hallucinogenic and require in clinic supervision of treatment. 🔥MB22001 is taken at home and then a patient can get on with their day in the same way they would if they were taking any other medication. 🔥🔥 Multiple Phase 2B clinical trials are currently underway. And..more great developments in the pipeline. 😃

Sleep is vital for maintaining good physical and mental well-being. Often though, during times of stress and poor mental health, we suffer from deprived and disrupted sleep. It is part of the human condition. So, when we discovered in clinical trials that microdosing MB22001 improved sleep, we were delighted because MB22001 appears to be well tolerated with few side effects and showing promise for treating depression. It has shown in clinical trials to improve mood, energy and feelings of happiness and creativity in healthy individuals and to reduce depressive symptoms in Major Depressive Disorder. The research is ongoing in multiple Phase 2B randomized controlled clinical trials currently underway and looking very promising for changing the treatment landscape and opening up new options for treating mental health conditions. I love the science, and the chance of discovering something novel through good quality research. Here we celebrate our scientific collaborator's incredible achievement of having their sleep research published in the prestigious Nature portfolio journal Translational Psychiatry. It is quite an achievement and a big well done to Nathan, Suresh, Robin, Rachael, Anna, Nicholas, David, William, Fred and Partha Roop Some of the best scientific minds and genuinely good people I have the privilege to continue to work with! Well done and thank you for this terrific contribution to science.

Phase 2B Microdosing (MB22001) in Depression take-home trial begins first dosing!

Very excited to share the next stage of developing this promising depression treatment. 🔥 First dosing has started in a Phase 2B take-home microdosing (MB22001) clinical trial in patients with Major Depressive Disorder. In a series of world first trials, patients are sent home under regulatory approvals with MB22001, a proprietary, titratable form of LSD designed for safe take-home microdosing. 👨🏫 MB22001, in a large Phase 1 randomized controlled clinical trial is already shown to improve feelings of wellbeing, happiness, energy, creativity and social connectivity in healthy individuals. Trial participants also slept better, including longer REM sleep and felt less irritable and angry. 🔥🔥 This Phase 2B trial follows a recent successful Phase 2A trial which resulted in 53% of depressed patients being in complete remission from their depression after 8 weeks. Overall, the trial resulted in a 60% drop in depressive symptoms, a 14.1 drop in MADRS score, (Montgomery-Asberg Depression Rating Scale). 🙏 We must innovate to create better treatments for mental health conditions. This is looking very promising as a potential scalable solution to using psychedelic medicines (without the hallucinations) in patients at home.